India · Delayed Price · Currency is INR Torrent Pharmaceuticals Statistics
Total Valuation
NSE:TORNTPHARM has a market cap or net worth of INR 1.55 trillion. The enterprise value is 1.77 trillion.
| Market Cap | 1.55T |
| Enterprise Value | 1.77T |
Important Dates
The last earnings date was Friday, May 22, 2026.
| Earnings Date | May 22, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
| Current Share Class | 338.45M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 0.28% |
| Owned by Institutions (%) | 17.54% |
| Float | 103.98M |
Valuation Ratios
The trailing PE ratio is 71.57 and the forward PE ratio is 63.28.
| PE Ratio | 71.57 |
| Forward PE | 63.28 |
| PS Ratio | 11.08 |
| PB Ratio | 8.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 66.02 |
| P/OCF Ratio | 51.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 38.89, with an EV/FCF ratio of 75.34.
| EV / Earnings | 81.68 |
| EV / Sales | 12.64 |
| EV / EBITDA | 38.89 |
| EV / EBIT | 51.37 |
| EV / FCF | 75.34 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.85.
| Current Ratio | 1.13 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | 3.31 |
| Debt / FCF | 6.41 |
| Interest Coverage | 8.94 |
Financial Efficiency
Return on equity (ROE) is 16.99% and return on invested capital (ROIC) is 12.57%.
| Return on Equity (ROE) | 16.99% |
| Return on Assets (ROA) | 7.25% |
| Return on Invested Capital (ROIC) | 12.57% |
| Return on Capital Employed (ROCE) | 9.56% |
| Weighted Average Cost of Capital (WACC) | 4.77% |
| Revenue Per Employee | 7.66M |
| Profits Per Employee | 1.18M |
| Employee Count | 18,258 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, NSE:TORNTPHARM has paid 7.34 billion in taxes.
| Income Tax | 7.34B |
| Effective Tax Rate | 25.56% |
Stock Price Statistics
The stock price has increased by +42.59% in the last 52 weeks. The beta is 0.15, so NSE:TORNTPHARM's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +42.59% |
| 50-Day Moving Average | 4,299.28 |
| 200-Day Moving Average | 3,964.16 |
| Relative Strength Index (RSI) | 61.51 |
| Average Volume (20 Days) | 572,307 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:TORNTPHARM had revenue of INR 139.80 billion and earned 21.63 billion in profits. Earnings per share was 63.92.
| Revenue | 139.80B |
| Gross Profit | 105.92B |
| Operating Income | 34.40B |
| Pretax Income | 28.72B |
| Net Income | 21.63B |
| EBITDA | 44.97B |
| EBIT | 34.40B |
| Earnings Per Share (EPS) | 63.92 |
Balance Sheet
The company has 23.55 billion in cash and 150.26 billion in debt, with a net cash position of -126.70 billion.
| Cash & Cash Equivalents | 23.55B |
| Total Debt | 150.26B |
| Net Cash | -126.70B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 175.85B |
| Book Value Per Share | 247.85 |
| Working Capital | 10.50B |
Cash Flow
In the last 12 months, operating cash flow was 30.23 billion and capital expenditures -6.77 billion, giving a free cash flow of 23.45 billion.
| Operating Cash Flow | 30.23B |
| Capital Expenditures | -6.77B |
| Depreciation & Amortization | 10.57B |
| Net Borrowing | 118.67B |
| Free Cash Flow | 23.45B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.76%, with operating and profit margins of 24.60% and 15.48%.
| Gross Margin | 75.76% |
| Operating Margin | 24.60% |
| Pretax Margin | 20.55% |
| Profit Margin | 15.48% |
| EBITDA Margin | 32.17% |
| EBIT Margin | 24.60% |
| FCF Margin | 16.78% |
Dividends & Yields
This stock pays an annual dividend of 38.00, which amounts to a dividend yield of 0.83%.
| Dividend Per Share | 38.00 |
| Dividend Yield | 0.83% |
| Dividend Growth (YoY) | 18.75% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 59.58% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.83% |
| Earnings Yield | 1.40% |
| FCF Yield | 1.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:TORNTPHARM is 4,878.79, which is 6.73% higher than the current price. The consensus rating is "Buy".
| Price Target | 4,878.79 |
| Price Target Difference | 6.73% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 18.71% |
| EPS Growth Forecast (3Y) | 19.71% |
Stock Splits
The last stock split was on July 8, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jul 8, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
NSE:TORNTPHARM has an Altman Z-Score of 3.65 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.65 |
| Piotroski F-Score | 4 |